AUA 2023: PSA Response and Time-to-Ca... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

AUA 2023: PSA Response and Time-to-Castration Resistance Among Patients with mCSPCa Initiated on Apalutamide, Enzalutamide, or Abiraterone

skiingfiend profile image
2 Replies

The objective of this study was to describe a “real-world” experience of mCSPC patients treated with apalutamide, enzalutamide, and abiraterone acetate, with a focus on PSA response and development of castration resistance outcomes.

This study identified patients with mCSPC newly initiated on apalutamide, enzalutamide, or abiraterone acetate using data from 77 community-based urology practices between September 2018 and April 2022.

-------------------------------------------------------

In this shootout:

apalutamide ranked 1st on all measures

enzalutamide ranked 2nd on all measures

abiraterone ranked 3rd on all measures

-------------------------------------------------------

How much should I care?

1. This is doublet therapy so does not include triplet therapy which is another emerging effective option.

2. You can find other shootouts where the rankings are rearranged.

3. Consult with your MO for your best treatment selection based on your unique circumstances.

-------------------------------------------------------

Also the newer AR targeted agent, Darolutamide, is not included since it has not been approved for doublet therapy in mCSPCa (triplet only) yet. Doublet approval for Darolutamide will be coming soonish, due to 2 new phase 3 RCT's.

See more about these new trials here:

ARASEC Trial, watch video here:

urotoday.com/trials-in-prog...

ARANOTE Trial, watch video here:

urotoday.com/video-lectures...

Written by
skiingfiend profile image
skiingfiend
To view profiles and participate in discussions please or .
Read more about...
2 Replies
skiingfiend profile image
skiingfiend

Meant to add a link to the news release:

read the news release here:

urotoday.com/conference-hig...

androgeen profile image
androgeen

Good morning,

The question with regard to the use of Enzalutamide for the treatment of metastatic prostate cancer can be answered. The effect of reducing the testosterone levels and thereby reducing the psa levels in blood was effective over a much longer period of time with previously taken medication. The problem encountered when this drug is administered that side effects can occur that need to be monitored dizziness headaches. Hope it will work out to your needs, With my greetings

You may also like...

Cardiotoxicity of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

campaign=impact-of-hormonal-therapies-for-treatment-of-hormone-dependent-cancers-on-the-cardiovascul

Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced PCa

testosterone in patients with CRPC that has become resistant to abiraterone or enzalutamide...

FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

com/view/fda-and-ema-approval-sought-for-darolutamide-plus-docetaxel-in-metastatic-hormone-sensitive

UK - Abiraterone too expensive for non-CRPC mPCa?

treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate...

Pluvicto increases radiographic progression-free survival (rPFS) before chemo

of the second-line hormonals (abiraterone, enzalutamide, darolutamide, or apalutamide) (2) have...